ASH 2023 | Treating elderly, non-transplant eligible patients with MF
Aaron Gerds, MD, Cleveland Clinic, Cleveland, OH, discusses the approach to treating elderly patients with myelofibrosis (MF) who are not eligible for allogeneic stem cell transplantation (alloSCT). In many elderly individuals, transplant is not an option due to comorbidities or frailty, and in these patients, it is crucial to select a treatment option that will maximize quantity and quality of life while minimizing adverse events and treatment-related hospitalizations. Dr Gerds highlights that ruxolitinib is a great therapeutic option in this patient population if bone marrow function is adequate. However, alternative JAK inhibitors, such as momelotinib or pacritinib, may be used if this is not the case. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: AbbVie, Bristol Myers Squibb, Constellation Pharmaceuticals, GlaxoSmithKline, Kartos, Novartis, PharmaEssentia, Sierra Oncology
Research Funding: Accurate Pharmaceuticals, Constellation Pharmaceuticals, CTI BioPharma, Imago BioSciences, Incyte Corporation, Kratos Pharmaceuticals
